

RECEIVED

MAY 15 2002

TECH CENTER 1600/2900

1635



1600

RAW SEQUENCE LISTING

DATE: 05/07/2002

PATENT APPLICATION: US/09/945,166A

TIME: 13:18:06

Input Set : A:\Mga00301.app

Output Set: N:\CRF3\05072002\I945166A.raw

ENTERED

3 <110> APPLICANT: ELMALEH, DAVID R.
 4 FISCHEMAN, ALAN J.
 5 BABICH, JOHN W.
 7 <120> TITLE OF INVENTION: TARGETED NUCLEIC ACID CONSTRUCTS AND USES RELATED
 8 THERETO
 10 <130> FILE REFERENCE: MGA-003.01
 12 <140> CURRENT APPLICATION NUMBER: 09/945,166A
 13 <141> CURRENT FILING DATE: 2001-08-31
 15 <160> NUMBER OF SEQ ID NOS: 7
 17 <170> SOFTWARE: PatentIn Ver. 2.1
 19 <210> SEQ ID NO: 1
 20 <211> LENGTH: 26
 21 <212> TYPE: PRT
 22 <213> ORGANISM: Artificial Sequence
 24 <220> FEATURE:
 25 <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative
 26 peptide
 28 <400> SEQUENCE: 1
 29 Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys Arg
 30 1 5 10 15
 32 Arg Gln Arg Arg Arg Pro Pro Gln Gly Ser
 33 20 25
 36 <210> SEQ ID NO: 2
 37 <211> LENGTH: 12
 38 <212> TYPE: PRT
 39 <213> ORGANISM: Artificial Sequence
 41 <220> FEATURE:
 42 <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative
 43 EGF derived peptide
 45 <400> SEQUENCE: 2
 46 Cys Met His Ile Glu Ser Leu Asp Ser Tyr Thr Cys
 47 1 5 10
 50 <210> SEQ ID NO: 3
 51 <211> LENGTH: 12
 52 <212> TYPE: PRT
 53 <213> ORGANISM: Artificial Sequence
 55 <220> FEATURE:
 56 <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative
 57 EGF derived peptide
 59 <400> SEQUENCE: 3
 60 Cys Met Tyr Ile Glu Ala Leu Asp Lys Tyr Ala Cys
 61 1 5 10
 64 <210> SEQ ID NO: 4

RAW SEQUENCE LISTING

DATE: 05/07/2002

PATENT APPLICATION: US/09/945,166A

TIME: 13:18:06

Input Set : A:\Mga00301.app

Output Set: N:\CRF3\05072002\I945166A.raw

65 <211> LENGTH: 32
 66 <212> TYPE: PRT
 67 <213> ORGANISM: Artificial Sequence
 69 <220> FEATURE:
 70 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 71 peptide
 73 <220> FEATURE:
 74 <221> NAME/KEY: MOD_RES
 75 <222> LOCATION: (1)
 76 <223> OTHER INFORMATION: Preferably a unique residue, such as Cys or Lys
 78 <220> FEATURE:
 79 <221> NAME/KEY: MOD_RES
 80 <222> LOCATION: (2)..(3)
 81 <223> OTHER INFORMATION: Variable amino acid
 83 <400> SEQUENCE: 4
 84 Xaa Xaa Xaa Glu Ala Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu Ala
 85 1 5 10 15
 87 Glu Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu Glu Ala Leu Ala Ala
 88 20 25 30
 91 <210> SEQ ID NO: 5
 92 <211> LENGTH: 8
 93 <212> TYPE: PRT
 94 <213> ORGANISM: Artificial Sequence
 96 <220> FEATURE:
 97 <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative
 98 peptide substrate for N-myristoyl transferase
 100 <400> SEQUENCE: 5
 101 Gly Asn Ala Ala Ala Arg Arg
 102 1 5
 105 <210> SEQ ID NO: 6
 106 <211> LENGTH: 18
 107 <212> TYPE: DNA
 108 <213> ORGANISM: Artificial Sequence
 110 <220> FEATURE:
 111 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 112 oligonucleotide
 114 <400> SEQUENCE: 6
 115 gtgtcgggggt ctccgggc 18
 118 <210> SEQ ID NO: 7
 119 <211> LENGTH: 18
 120 <212> TYPE: DNA
 121 <213> ORGANISM: Artificial Sequence
 123 <220> FEATURE:
 124 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
 125 oligonucleotide
 127 <400> SEQUENCE: 7
 128 gcccgagac cccgacac 18

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/945,166A

DATE: 05/07/2002
TIME: 13:18:07

Input Set : A:\Mga00301.app
Output Set: N:\CRF3\05072002\I945166A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:4; Xaa Pos. 1,2,3